327619-41-0

Basic information

• Product Name: N-(2,4-dimethylphenyl)-2,6-difluorobenzamide
• CAS NO: 327619-41-0
• Molecular Formula: C₁₅H₁₂F₂N₂O₃
• Molecular Weight: 261.2666
• Mol File: 327619-41-0.mol

Chemical Properties

• Boiling Point: 291.615°C at 760 mmHg
• Flash Point: 130.164°C
• Density: 1.248g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.588
• CAS DataBase Reference: N-(2,4-dimethylphenyl)-2,6-difluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-dimethylphenyl)-2,6-difluorobenzamide(327619-41-0)
• EPA Substance Registry System: N-(2,4-dimethylphenyl)-2,6-difluorobenzamide(327619-41-0)

Safety Data

• Hazardous Substances Data: 327619-41-0(Hazardous Substances Data)

Upstream product

• 1635-84-3 2,4-Dimethyl-6-nitroanilin 
• 18063-02-0 2,6-difluorobenzoylchloride 

Downstream Products

• 327619-42-1 2-(2,6-difluorophenyl)-4,6-dimethylbenzimidazole 

Relevant articles and documents

Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme

In an ongoing effort to develop novel and potent nonnucleoside HIV-1 reverse transcriptase (RT) inhibitors that are effective against the wild type (WT) virus and clinically observed mutants, 1,2-bis-substituted benzimidazoles were synthesized and tested. Optimization of the N1 and C2 positions of benzimidazole led to the development of 1-(2,6-difluorobenzyl)-2-(2,6- difluorophenyl)-4-methylbenzimidazole (1) (IC50 = 0.2 μM, EC 50 = 0.44 μM, and TC50 ≥ 100 against WT). This paper describes how substitution on the benzimidazole ring profoundly affects activity. Substituents at the benzimidazole C4 dramatically enhanced potency, while at C5 or C6 substituents were generally detrimental or neutral to activity, respectively. A 7-methyl analogue did not inhibit HIV-1 RT. Determination of the crystal structure of 1 bound to RT provided the basis for accurate modeling of additional analogues, which were synthesized and tested. Several derivatives were nanomolar inhibitors of wild-type virus and were effective against clinically relevant HIV-1 mutants.

Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection

The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.